---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-248244"
form_type: "8-K"
ticker: "NMRA"
cik: "0001885522"
company_name: "Neumora Therapeutics, Inc."
filed_at: "2026-05-29T20:05:20+00:00"
generated_at: "2026-05-29T20:08:14.757587+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Neumora Therapeutics annual meeting elects directors, ratifies auditor, approves executive compensation

## Summary
- Directors Paul L. Berns, Matthew Fust, David Piacquad elected with ~126M, ~125M, ~127M votes for, respectively; ~25M broker non-votes.
- Ernst & Young ratified as independent auditor for FY 2026 with 157.6M votes for, 53.6K against.
- Advisory vote on named executive officer compensation approved: 132.0M for, 420.9K against, 25.0M broker non-votes.
- Advisory vote on say-on-pay frequency: majority selected one year; company will hold annual advisory votes on executive compensation.

## SEC filing metadata
- accession: 0001193125-26-248244
- form_type: 8-K
- ticker: NMRA
- cik: 0001885522
- company_name: Neumora Therapeutics, Inc.
- filed_at: 2026-05-29T20:05:20+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1885522/000119312526248244/0001193125-26-248244-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1885522/000119312526248244/d18793d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-248244
- JSON: https://secwatch.observer/filing/0001193125-26-248244.json
- Plain text: https://secwatch.observer/filing/0001193125-26-248244.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.